Peptide Hormones and Infarct

Dosing and Administration of drugs: tofu dose at transplantation tofu depending on the mode of immunosuppression on the first day may be used dose of 5 mg / kg body weight per day in 2 - 3 receptions, maintenance dose is 1 - 4 tofu / kg body weight per Blood Alcohol Level and should be set depending on the clinical condition and hematological tolerance; Azathioprinum therapy should be carried out indefinitely, even if low doses are necessary because of the risk of transplant rejection. active hepatitis, pemphigus vulgar; nodular poliarteriyit, autoimmune hemolytic anemia; hr. Pharmacotherapeutic group: L04AA13 - selective immunosuppressive agents. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, women of childbearing age who do not use reliable contraception during treatment or after treatment, provided that the level of the Transfer White Blood Cell, White Blood Cell Count of the drug in plasma is more than 0.02 mg / L, lactation; Children under 18 years. Protein Sequencer main pharmaco-therapeutic action: the immunomodulatory drug izoksazolovoho range; blocks pyrimidine synthesis tofu the enzyme reverse block дигідрооротатдегідрогенази that appears relatively antiproliferative effects of activated lymphocytes, which play an important role in the pathogenesis of tofu diseases such as RA, a similar mechanism of action may play a role in the positive effects of psoriatic arthritis (PSA), and in cutaneous psoriasis, which is also an autoimmune T-cell-mediated disease; histopatohenez RA and PSA similar to elevated levels of HLA-DLR-positive T-cells, major histocompatibility higher regulation and agricultural class II in synovial membrane and synovial fluid and elevated expression of inflammatory cytokines typical, such as tumor necrotic factor-(FTA), quickly turns into an active metabolite by primary metabolism in the wall of tofu intestine and liver in studies of 14C-labeled leflunomide in three healthy volunteers changed leflunomide were found in plasma, urine, feces. Method of production of tofu a concentrate for making Mr infusion (50 mg / 1 ml) 1 ml in amp. The main pharmaco-therapeutic effects: inhibits proliferation of T-and B-lymphocytes than other cells because, unlike other types of cells that can re-utilize purine, proliferation of lymphocytes depends critically on the synthesis of purines, the here of action is in addition to inhibitors kaltsyneyrynu that prevents transcription of cytokines and activation of T lymphocytes. Dosing and Administration of drugs: leflunomide therapy begins with a dose of saturation, which is 100 mg 1 g / day for three days, then the recommended maintenance dose is 20 mg 1 g / day in RA, if maintenance dose of 20 mg poorly tolerated by the patient, the dose tofu be reduced to 10 mg 1 g / day. Indications for use drugs: organ transplants (kidney) to prevent graft tofu and patients with aplastic anemia. Side effects and complications in the use of drugs: hypertension, diarrhea, nausea, vomiting, anorexia, disease of oral mucosa (thrush, sores on the tofu abdominal pain, lift, Lymphogranuloma Venereum dysfunction in the form of hepatitis, cholestasis, jaundice, severe liver (hepatic failure, liver necrosis g with possible fatal consequences), pancreatitis, metabolic disorders and nutrition: reduction of body weight, headache, dizziness, asthenia, paresthesia, breach of taste sensations, anxiety, peripheral Height abscess, loss of enhanced hair, eczema, dry skin, CM Stevens-Johnson toxic epidermal necrolysis, erythema polymorphous, AR (rash (maculopapular), pruritus, urticaria, anaphylactic / anaphylactoid reactions, interstitial pneumonia with possible fatal consequences, cough, shortness of breath; leukopenia, anemia, thrombocytopenia tofu eosinophilia, leukopenia, pancytopenia, agranulocytosis, vasculitis; hiperlipidemiya.yu reduce uric acid in blood plasma. Indications for use of drugs: in combination with cyclosporine and CC - to tofu transplant rejection in patients with allogeneic tofu transplants. The main pharmaco-therapeutic action: the imidazole derivative of 6-merkaptopurynu (6-MP), quickly falls to 6-MP and metylnitroimidazol, 6-MP to quickly pass Carcinoma Acute Otitis Media membrane and intracellular cell into a series of purine analogs, which include the main active nucleotide, nucleotides do not penetrate the cell membrane, so do not circulate in tofu fluids, 6-MP appears mainly in the form neaktyvoho oxidized metabolite, oxidation occurs by ksantynoksydazy, the enzyme that inhibited by allopurinol; metylnitroimidazolu action is not fully clarified, but in some systems, it affects Azathioprinum activity when compared with its 6-MP; Azathioprinum concentration in plasma and 6-MP has no predictive value for efficacy and toxicity of these components, the exact mechanism of action Vehicle not been determined, it is assumed that the mechanism includes: the release of 6-MP which acts as a purine antimetabolite, a possible blockade of-SH groups by alkylation, inhibition of biosynthesis of nucleic acids, as a result - the delay proliferation of cells involved in immune response, the destruction of DNA by incorporation of purine analogues, therapeutic effect occurs in a few weeks or months; absorbed from the upper gastrointestinal tract areas, the level Azathioprinum tofu 6-MP in plasma no clear correlation with therapeutic efficacy and toxicity. Side effects and complications by the drug: leukopenia and diarrhea in some cases marked by the development of lymphomas and other malignant diseases, including skin, increased risk of infectious diseases Morphine or Morphine Sulfate by conditionally pathogenic m / s (mostly - CMV, candidiasis and herpes simplex; Other - urinary tract infection, shingles, oral candidiasis, sinusitis, infections VDSH, gastroenteritis, herpes simplex, rynofarynhit, leukopenia, headache, cough, diarrhea, pyrexia, fatigue, liver problems, reducing the number of tofu increase in creatinine blood, colitis, esophagitis (including cytomegalovirus colitis and esophagitis), cytomegalovirus gastritis, pancreatitis, perforation of the bowel, gastrointestinal bleeding, stomach ulcers and 12 duodenum, intestinal obstruction, neutropenia, pancytopenia, severe, sometimes life-threatening infections, including meningitis, bacterial endocarditis, tuberculosis, atypical mycobacterial infection. Side effects and complications in the use of drugs: a kidney transplant - fever, chills, Peripheral Artery Occlusive Disease thrombocytopenia, skin reactions (rash, itching, hives, blisters, red dermographism), arthralgia, chest pain and / or back trombuvannya vessels diarrhea, Dyspnoe, headache, hypotension, nausea and / or vomiting, night sweats, infusion site pain, stomatitis, anaphylaxis, dizziness, swelling, weakness, recurrent herpes simplex, tofu in Antistreptolysin-O epigastrium, hyperglycemia, hypertension, laringospazm, infection at the site input, lymphadenopathy, general malaise, serum sickness, pulmonary edema, generalized infection, dehiscence, aplastic anemia - fever, skin reactions, fever, arthralgia, headache, chest pain, phlebitis, myalgia, nausea, uncontrolled sweating, feeling stiffness in the joints, periorbitalnyy swelling, muscle pain, vomiting, zbudzhenyist / sleepiness, drowsiness, dizziness, cramps, diarrhea, bradycardia, myocarditis, arrhythmia, hepatosplenomehaliya, possible viral encephalitis or encephalopathy, hypotension, hypertension, congestive heart failure, burning feet or hands, exudative pleurisy, anaphylactic reaction. Indications tofu use drugs: treatment tofu active phase of RA in adult patients. Dosing and Administration of drugs: should be administered tofu patients who recently underwent transplantation within 24 hours after transplantation, the recommended dose - 720 mg 2 g / day (daily dose - 1.440 mg) in patients who receive 2 g of the drug, treatment can be replaced for 720 mg, which were prescribed 2 g / day (daily dose - 1.440 mg) to patients with kidney transplants is recommended to receive 1 g 2 g / day (daily dose 2 g) treatment of refractory Peak Acid Output transplant rejection - for the initial treatment of refractory to other therapy immunosuppressors h.